Subject Index
PDF

Other

Subject Index

J Clin Res Pediatr Endocrinol 2020;12(4):0-0
PDF
Permissions

1 year of age 248

11β-hydroxylase deficiency 288

46,XX disorder of sex development 109, 206

46,XX ovotesticular disorder of sex development 308

AAP 125

Abetalipoproteinemia 223

Abnormal external genitalia 113

Abnormal uterine bleeding 1*suppl

Accelerator hypothesis 281

Adherence 225

Adiponectin 180

Adolescence 17

Adolescent 1*suppl, 18*suppl, 28*suppl, 41*suppl, 46*suppl, 50*suppl, 233

Adrenal hypoplasia 206

Adrenal insufficiency 241

Adult height 71

Alkaline phosphatase 104

Androgen-insensitivity syndrome 50*suppl

Anti-Müllerian hormone 79

Application 125

Aromatase deficiency 109

Autoimmune thyroiditis 303

Bisphenol A 86

Body fat percentage 168

Body mass index 281

Calculator 125

Carney complex 117

Central hypothyroidism 218, 223

Central precocious puberty 37

Central puberty precocious 117

Childhood 17, 241

Children 29, 86, 180, 281, 329

Children and adolescents 45

Coagulopathy 1*suppl

Combined pituitary hormone deficiency 212, 261

Congenital adrenal hyperplasia 288

Congenital hypothyroidism 275, 303

Contraception 28*suppl

Contraceptive services 28*suppl

Counselling 28*suppl

CYP19A1 gene 109

Cyprus 175

D-lactate 160

Deficiency 248

Developmental disabilities 41*suppl

Diabetes mellitus 189, 315

Diabetic ketoacidosis 160, 189

Diagnosis 18*suppl

Double diabetes 55

Dysmenorrhea 7*suppl

Education 95

eHealth 225

Endometriosis 7*suppl

Epimutation 1

Euthyroid sick syndrome 143, 223

Family planning 28*suppl

Final height 295

Functional 18*suppl

Genotype 1

GLI2 mutations 319

Glycemic control 233

GnRH 37

GnRH analogue 37

Gonadotropin releasing hormone agonist 37

Graves’ disease 197

Growth 225

Growth chart 125

Growth disorders 130

Growth hormone 225

Growth hormone deficiency 319

Growth hormone treatment 295

Growth velocity 71

Guideline 125

Heavy menstrual bleeding 1*suppl

Hormone replacement therapy 46*suppl

Human growth hormone treatment 71

Hydroxymethylfurfural 79

Hypertension 29, 125

Hypogonadism 46*suppl

Hypophosphatasia 104

Hypophosphatemic rickets 151

Hypopituitarism 261

Hypoprolactinemia 218

Hypothalamic amenorrhea 18*suppl

IGF-I 130

IGFBP-3 130

IGSF1 218

Imprinting disorders 1

Incidence 288

Incidence rate 175

Increased intestinal permeability 303

Insulin 189

Insulin resistance 180

Internipple distance 269

Internipple index 269

Intramuscular ACTH 241

Iodine 329

Iodine deficiency 256

Irisin 168

Ischemia-modified albumin 45

Isolated growth hormone deficiency 295

Knowledge levels 95

Large cell calcifying Sertoli cell tumor 117

Leuprolide 37

Lipodystrophy 17

Liquid chromatography-mass spectrometry 86

Long acting reversible contraception 28*suppl

Macular retinal thickness 63

Macular retinal volume 63

Male adolescent 168

Menstruation 41*suppl

Metabolic syndrome 55, 63, 180

Metformin 315

Metreleptin 17

MIRAGE syndrome 206

Missense mutation 212

Mobile 125

Motivational interviewing 225

Multiple pituitary hormone deficiency 295, 319

Muscle mass 168

Mutation 104

Müllerian aplasia 50*suppl

Myocarditis 160, 202

National Prophylaxis Program 248

Neonatal screening 288

Nesfatin-1 29

Neurofibromatosis Noonan syndrome 113

Neurofibromatosis type-1 202

Newborn 104

NF1 gene 113

Obesity 29, 45, 180

Optical coherence tomography 63

Oral contraceptive pills 1*suppl

Orthorexic eating behavior 233

Osteochondromyxoma 117

Pediatric obesity 63

Pediatric or childhood chronic liver diseases 143

Pediatric transport 189

Pelvic pain 7*suppl

Permanent 275

Phenotype 1

Pheochromocytoma 202

PHEX 151

Pituitary stalk interruption syndrome 71, 212

Pituitary transcription factors 261

Polydactyly 319

Precocious puberty 37

Pregnancy in adolescence/prevention and control 28*suppl

Prehospital care 189

Prevalence 55, 256

Prevention 315

Progeria 17

Progeria syndrome 315

PROP1 gene 261

Puberal stage 168

Puberty 37, 79, 295

Questionnaire 95

Rat 79

Receptor Roundabout-1 gene 212

Reliability 241

Risk behaviors 233

School-age children 256

Second-tier 288

Short stature 125, 130

Six month L-thyroxine dose 275

Soluble CD40 ligand (sCD40L) 197

Soluble receptor for advanced glycation end-products 160

SOX9 308

SRY-negative 308

Steroid profiling 288

Subclinical hypothyroidism 143

Thiol/disulfide homeostasis 45

Thyroid function test 143

Thyroid hormone 197

Thyroid volume 197

Transient 275

Treatment 18*suppl, 151

Turkey 86, 256, 269, 329

Turner syndrome 95

Type 1 diabetes 55, 175, 233, 281

Urinary iodine concentration 329

Urine 86

Vaginal opening 79

Vitamin D 248

Zonulin 303